IMRX Immuneering Corporation
Immuneering Corporation (IMRX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: June 23, 2026 , by Zeskind Benjamin J. .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 2,400 | $4.56 | $10.9K | 2,315,252 | |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 6,035 | $4.15 | $25.0K | 382,531 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.